Oral Session 3-7A DLBCL: Elderly/Others

[OS3-7A-2] Validation of NCCN-IPI for patients with diffuse large B-cell lymphoma treated in the rituximab era

Norihito Inoue¹, Masahiro Yokoyama¹, Anna Nishihara¹, Hirofumi Yamauchi^1,4, Yoshiharu Kusano¹, Yuko Mishima¹, Noriko Nishimura¹, Shoko Marshall⁴, Naoko Tsuyama³, Kengo Takeuchi², Kiyohiko Hatake⁵, Yasuhito Terui¹ (1.Hematology and Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan, 2.Pathology Project for Molecular Targets Project, Cancer Institute, Tokyo, Japan, 3.Pathology, Cancer Institute, Tokyo, Japan, 4.Medical Oncology, Cancer Institute Hospital of JFCR, Tokyo, Japan, 5.Hematology, International University of Health and Welfare, School of Medicine.)